Top
Summary
All studies
Mortality
Ventilation
Hospitalization
Serious outcomes
Recovery
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All cenicriviroc studies
..
Feedback
Home
c19early.org COVID-19 treatment researchCenicrivirocCenicriviroc (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 cenicriviroc studies

Home
Post
Share
@CovidAnalysis
StudiesStudies
FeedbackFeedback
All studies   Mortality   Ventilation   Hospitalization   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -28% 3 1,000 Improvement, Studies, Patients Relative Risk Mortality -28% 3 1,000 Ventilation -167% 1 30 Hospitalization -17% 1 29 Recovery -2% 3 1,013 RCTs -28% 3 1,000 RCT mortality -28% 3 1,000 Late -28% 3 1,000 Cenicriviroc for COVID-19 c19early.org December 2024 Favorscenicriviroc Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] death 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] death 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] death 64/355 49/354 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 studies c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Effect extraction pre-specified(most serious outcome) Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] 64/355 49/354 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 mortality results c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kurth (DB RCT) -167% 2.67 [0.12-60.5] 1/18 0/12 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.55 Late treatment -167% 2.67 [0.12-60.5] 1/18 0/12 167% higher risk All studies -167% 2.67 [0.12-60.5] 1/18 0/12 167% higher risk 1 cenicriviroc COVID-19 mechanical ventilation result c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.55 Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kurth (DB RCT) -17% 1.17 [0.80-1.69] hosp. time 17 (n) 12 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.42 Late treatment -17% 1.17 [0.80-1.69] 17 (n) 12 (n) 17% higher risk All studies -17% 1.17 [0.80-1.69] 17 (n) 12 (n) 17% higher risk 1 cenicriviroc COVID-19 hospitalization result c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.42 Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] death 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] death 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] death 64/355 49/354 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 serious outcomes c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Effect extraction pre-specified(most serious outcome) Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -14% 1.14 [0.81-1.59] no recov. 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -100% 2.00 [0.29-25.0] no recov. 17 (n) 12 (n) ACTIV-1 IM O’Halloran (DB RCT) 1% 0.99 [0.85-1.16] no recov. 360 (n) 363 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.82 Late treatment -2% 1.02 [0.88-1.17] 469 (n) 544 (n) 2% higher risk All studies -2% 1.02 [0.88-1.17] 469 (n) 544 (n) 2% higher risk 3 cenicriviroc COVID-19 recovery results c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.82 Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] death 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] death 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] death 64/355 49/354 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 Randomized Controlled Trials c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Effect extraction pre-specified(most serious outcome) Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] 64/355 49/354 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 RCT mortality results c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] death 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] death 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] death 64/355 49/354 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 peer reviewed studies c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.057 Effect extraction pre-specified(most serious outcome) Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] death 92 (n) 169 (n) Improvement, RR [CI] Treatment Control I-SPY COVID Files (RCT) -14% 1.14 [0.81-1.59] no recov. 92 (n) 169 (n) Kurth (DB RCT) -167% 2.67 [0.12-60.5] death 1/18 0/12 Kurth (DB RCT) -167% 2.67 [0.12-60.5] ventilation 1/18 0/12 Kurth (DB RCT) -500% 6.00 [0.34-107] oxygen 3/18 0/12 Kurth (DB RCT) -100% 2.00 [0.29-25.0] no recov. 17 (n) 12 (n) Kurth (DB RCT) -17% 1.17 [0.80-1.69] hosp. time 17 (n) 12 (n) ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] death 64/355 49/354 ACTIV-1 IM O’Halloran (DB RCT) -16% 1.16 [0.79-1.71] death 49/355 42/354 ACTIV-1 IM O’Halloran (DB RCT) -8% 1.08 [0.81-1.41] no improv. 348 (n) 343 (n) ACTIV-1 IM O’Halloran (DB RCT) 1% 0.99 [0.85-1.16] no recov. 360 (n) 363 (n) Cenicriviroc COVID-19 outcomes c19early.org December 2024 Favors cenicriviroc Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0